Literature DB >> 10479498

Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.

F D Cirisano1, S J Robboy, R K Dodge, R C Bentley, H R Krigman, I S Synan, J T Soper, D L Clarke-Pearson.   

Abstract

PURPOSE: The aim of this study was to identify similarities and differences in epidemiologic and surgicopathologic staging results for papillary serous (PS) and clear cell (CC) endometrial cancers compared with endometrioid (EM) carcinoma of the endometrium.
METHODS: Clinical and surgicopathologic data were retrospectively collected on 574 clinical stage I-II endometrial cancer patients, including 53 PS and 18 CC (based on postoperative histology), undergoing hysterectomy at Duke University Medical Center between 1967 and 1990. All staging material was available and reexamined prior to this analysis, and FIGO surgical staging was retrospectively assigned. PS and CC histologic subtypes were compared both as a common category and as discrete categories versus EM, EM grade 1 (EM1), EM grade 2 (EM2), and EM grade 3 (EM3). Fisher's exact test was used to compare proportions with unordered categories (2x2 tables), while the chi(2) test for trend was used to compare proportions in 3x2 tables with ordered categories. Differences in medians were compared with the Wilcoxon rank-sum test.
RESULTS: PS tumors accounted for 8%, CC for 2%, and EM for 90% of cases. Overall, 14% of tumors were changed to a different postoperative histology including 64% of PS, 50% of CC, and 8% of EM. Postoperative histology changes were 4% for EM1 and 21% for EM3. PS, CC, and EM3 had more surgical sampling performed than for other EM. Rates for lymph node dissections were similar for EM3 (81%), PS (72%), and CC (67%) tumors, although metastases were more frequent for PS and CC compared with EM3. When PS tumors were confined to the endometrium, paraaortic metastases occurred in 13%. LVSI increased with EM grade and was highest for PS and CC. Upstaging to surgical stage III-IV occurred in 47% of PS, 39% of CC, and 12% of EM. The majority of PS and CC tumors were confined to the inner one-third of the myometrium, compared with EM tumors, where grade correlated with depth of myometrial invasion. Extrauterine metastases occurred in 55% of PS and 45% of CC tumors confined to the inner one-half, compared with 17% of EM3.
CONCLUSION: Frequent changes from preoperative to postoperative histology and grade may contribute to misassignment of preoperative and intraoperative risk as determined by depth of myometrial invasion for PS and CC patients. The higher frequency of extrauterine metastases in PS and CC tumors compared with EM3, despite similar surgical sampling rates, supports a more virulent behavior. The poor correlation between depth of myometrial invasion and risk for extrauterine metastases helps to explain poorer survival in PS and CC patients, in addition to more frequent upstaging. These results support routine extended surgical staging for women with preoperative or intraoperative diagnosis of PS and CC tumors. Intraoperative assessment of tumor grade and histology may be indicated and warrants further investigation. Copyright 1999 Academic Press.

Entities:  

Mesh:

Year:  1999        PMID: 10479498     DOI: 10.1006/gyno.1999.5505

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  30 in total

1.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Authors:  Shannon D Armbruster; Rebecca Previs; Pamela T Soliman; Shannon N Westin; Bryan Fellman; Anuja Jhingran; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2019-06-18       Impact factor: 5.482

2.  Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.

Authors:  Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

3.  Factors associated with Type I and Type II endometrial cancer.

Authors:  Ashley S Felix; Joel L Weissfeld; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Faina Linkov
Journal:  Cancer Causes Control       Date:  2010-07-14       Impact factor: 2.506

4.  Clear Cell Carcinoma of the Endometrium: Evaluation of Prognostic Parameters in a Multi-institutional Cohort of 165 Cases.

Authors:  Eman Abdulfatah; Sharif Sakr; Sumi Thomas; Zaid Al-Wahab; David G Mutch; Sean Dowdy; Sudeshna Bandyopadhyay; Adnan Munkarah; Mohamed Elshaikh; Robert Morris; Rouba Ali-Fehmi
Journal:  Int J Gynecol Cancer       Date:  2017-10       Impact factor: 3.437

5.  Comparison of outcomes in early-stage uterine clear cell carcinoma and serous carcinoma.

Authors:  Minsi Zhang; T Jonathan Yang; Neil B Desai; Deborah DeLair; Marisa A Kollmeier; Vicky Makker; Mario M Leitao; Nadeem R Abu-Rustum; Kaled M Alektiar
Journal:  Brachytherapy       Date:  2018-10-10       Impact factor: 2.362

Review 6.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

7.  Neoadjuvant chemotherapy followed by surgery for advanced-stage endometrial cancer.

Authors:  N M de Lange; N P M Ezendam; J S Kwon; I Vandenput; D Mirchandani; F Amant; L J M van der Putten; J M A Pijnenborg
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

Review 8.  Endometrial cancer: the management of high-risk disease.

Authors:  Gunnar Kristensen; Claes Tropé
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

9.  Clinical Significance of Serum HE4, CA125, CA724, and CA19-9 in Patients With Endometrial Cancer.

Authors:  Jing Bian; Xiaoxu Sun; Bo Li; Liang Ming
Journal:  Technol Cancer Res Treat       Date:  2016-08-24

10.  Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo.

Authors:  Salvatore Lopez; Carlton L Schwab; Emiliano Cocco; Stefania Bellone; Elena Bonazzoli; Diana P English; Peter E Schwartz; Thomas Rutherford; Roberto Angioli; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2014-08-27       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.